Trazimera 150 mg/7.15mL
trastuzumab-qyyp · INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · Pfizer Laboratories Div Pfizer Inc
Trazimera is a prescription injection used to treat HER2-positive breast cancer and gastric cancer by blocking the HER2 protein that helps cancer cells grow. It is given intravenously and belongs to a class of drugs called HER2/neu receptor antagonists.
Key Facts
- Brand Name
- Trazimera
- Generic Name
- trastuzumab-qyyp
- NDC Code (Product)
0069-0308- Manufacturer
- Pfizer Laboratories Div Pfizer Inc
- Strength
- 150 mg/7.15mL
- Dosage Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761081
- Drug Class
- HER2/neu Receptor Antagonist [EPC]
- Marketing Start
- 03/10/2021
Recall History
No Recall HistoryFrequently Asked Questions
What is Trazimera used for?
Trazimera is a prescription injection used to treat HER2-positive breast cancer and gastric cancer by blocking the HER2 protein that helps cancer cells grow. It is given intravenously and belongs to a class of drugs called HER2/neu receptor antagonists.
Is Trazimera a controlled substance?
Trazimera is not classified as a controlled substance by the DEA.
What is the generic name for Trazimera?
The generic name for Trazimera is trastuzumab-qyyp. There are no other listed brand versions of trastuzumab-qyyp.
What is the NDC code for Trazimera 150 mg/7.15mL?
The NDC (National Drug Code) for Trazimera 150 mg/7.15mL is 0069-0308, listed by Pfizer Laboratories Div Pfizer Inc.
Other Trazimera Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)